Gradalis Raises $24M For Cancer Vaccines

Dallas-based Gradalis announced this morning that it has raised $24M in a Series B round of financing, which will go towards financing late-stage trials of its personalized cancer vaccine. Gradalis is developing treatments for advanced stage cancer, which uses a patient's own cancer cells to develop vaccines to spur a better immune response to the disease. Source of the funding was not announced. The company said the funding will go to advance its vaccine through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch. More information »